Heart Clinic, University of Tartu, 1a L. Puusepa Str., 50406 Tartu, Estonia; Centre of Cardiology, North Estonia Medical Centre, 19 J. Sütiste Str., 13419 Tallinn, Estonia.
Heart Clinic, University of Tartu, 1a L. Puusepa Str., 50406 Tartu, Estonia; Centre of Cardiology, North Estonia Medical Centre, 19 J. Sütiste Str., 13419 Tallinn, Estonia; Quality Department, North Estonia Medical Centre, 19 J. Sütiste Str., 13419 Tallinn, Estonia.
Int J Cardiol. 2018 Dec 1;272:26-32. doi: 10.1016/j.ijcard.2018.08.015. Epub 2018 Aug 8.
The purpose was to describe the treatment and outcomes of non-ST-elevation myocardial infarction (NSTEMI) in Estonia according to patients' estimated mortality risk by the Global Registry of Acute Coronary Events (GRACE) score and investigate if inequalities in treatment had an impact on prognosis.
We performed a linkage between Estonian Myocardial Infarction Registry, Population Registry and Estonian Health Insurance Fund. All NSTEMI patients 2012-2014 were stratified into low (<4%), intermediate (4-12%), or high (>12%) mortality risk according to GRACE. All-cause mortality and composite endpoint of death, recurrent myocardial infarction, stroke or unplanned revascularization were compared between optimally - defined as concomitant in-hospital use of medicines from recommended groups and coronary angiography - and suboptimally managed patients, using the Cox regression.
Out of 3803 NSTEMI patients (median age 73 years, 44% women) 20% were classified into low, 35% into intermediate and 45% into high risk category. In these groups, respectively, 62%, 46% and 23% of patients received optimal in-hospital management. Over the mean follow-up of 2.4 years the association between suboptimal in-hospital management and outcomes was the following: in the low risk group mortality hazard ratio (HR) 1.6 (95% confidence interval 0.8-3.2), composite endpoint HR 1.2 (0.8-1.8); in the intermediate risk group mortality HR 2.4 (1.7-3.3), composite endpoint HR 1.8 (1.4-2.3); and in the high risk group mortality HR 2.2 (1.8-2.8), composite endpoint HR 1.6 (1.3-2.0).
Higher risk NSTEMI patients received less guideline-recommended in-hospital management, which was associated with a worse prognosis.
本研究旨在根据全球急性冠状动脉事件注册(GRACE)评分估计的死亡率风险,描述爱沙尼亚非 ST 段抬高型心肌梗死(NSTEMI)患者的治疗和结局,并探讨治疗中的不平等是否对预后产生影响。
我们将爱沙尼亚心肌梗死注册、人口登记和爱沙尼亚健康保险基金进行了链接。根据 GRACE,将 2012-2014 年所有 NSTEMI 患者分为低危(<4%)、中危(4-12%)和高危(>12%)风险人群。使用 Cox 回归比较最佳治疗(定义为同时使用推荐药物组和冠状动脉造影)和次优治疗患者的全因死亡率和死亡、复发性心肌梗死、卒中和计划外血运重建的复合终点。
3803 例 NSTEMI 患者(中位年龄 73 岁,44%为女性)中,20%为低危、35%为中危和 45%为高危。在这些患者中,分别有 62%、46%和 23%接受了最佳院内治疗。在平均 2.4 年的随访期间,次优院内治疗与结局之间的关系如下:低危组死亡率的危险比(HR)为 1.6(95%置信区间 0.8-3.2),复合终点 HR 为 1.2(0.8-1.8);中危组死亡率 HR 为 2.4(1.7-3.3),复合终点 HR 为 1.8(1.4-2.3);高危组死亡率 HR 为 2.2(1.8-2.8),复合终点 HR 为 1.6(1.3-2.0)。
高危 NSTEMI 患者接受的指南推荐院内治疗较少,预后较差。